Beyond cholesterol: The enigma of atherosclerosis revisited

Thrombosis and Haemostasis

Volumn 91, Issue 4, 2004, Pages 639-645

  Bhakdi, Sucharit ^a   Lackner, Karl J ^a   Han, Shan Rui ^a   Torzewski, Michael ^a   Husmann, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

C reactive protein; Cholesterol clearance; Complement; Low density lipoprotein

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; EPITOPE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROLASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; COMPLEMENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

APOPTOSIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; HUMAN; IMMUNE SYSTEM; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REVIEW; ARTERY INTIMA; ATHEROGENESIS; BIOCHEMISTRY; LIPID HYDROLYSIS; LIPID TRANSPORT; OXIDATION; PATHOLOGY; REGULATORY MECHANISM;

EID: 12344304519     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-12-0733     Document Type: Review

References (66)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104: 503-16.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
4. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91.
5. Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995; 96: 1389-94.
6. Matsumoto T, Saito E, Watanabe H, et al. Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1998; 139: 95-106.
7. Drew AF, Tipping PG. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 1995; 116: 181-9.
8. 2 Third Report of the National Cholesterol Education Program NCEP Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III final report. Circulation 2002; 106: 3143-421.
9. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
10. Stary HC. Natural history and histological classification of atherosclerotic lesions: An update. Arterioscler Thromb Vasc Biol 2000; 20: 1177-8.
11. Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive oil-red-O-negative particles. Am J Pathol 1984; 114: 201-8.
12. Kruth HS. Subendothelial accumulation of unesterified cholesterol. An early event in atherosclerotic lesion development. Atherosclerosis 1985; 57: 337-41.
13. Simionescu N; Vasile E; Lupu F; et al. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 1986; 123: 109-25.
14. Chao FF, Amende LM, Blanchette-Mackie EJ, et al. Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol 1988; 131: 73-83.
15. Zhang Y, Cliff WJ, Schoefl GI, et al. Plasma protein insudation as an index of early coronary atherogenesis. Am J Pathol 1993; 143: 496-506.
16. Stender S, Zilversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis 1981; 1: 38-49.
17. Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: Its possible role in atherogenesis. Adv Lipid Res 1982; 19: 1-53.
18. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 471-4.
19. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-4.
20. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
21. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-6.
22. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87: 5134-8.
23. Terkeltaub R, Banka CL, Solan J, et al. Oxidized LDL induces monocytic cell expression of interleukin-8 a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994; 14: 47-53.
24. Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182: 1959-71.
25. Kapinsky M, Torzewski M, Buchler C, et al. Enzymatically degraded LDL preferentially binds to CD14high CD16+ monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol 2001; 21: 1004-10.
26. van den Eijnden MM, van Noort JT, Hollaar L, et al. Cholesterol or triglyceride loading of human monocyte-derived macrophages by incubation with modified lipoproteins does not induce tissue factor expression. Arterioscler Thromb Vasc Biol 1999; 19: 384-92.
27. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
28. Kuhn H, Heydeck D, Hugou I, et al. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 1997; 99: 888-93.
29. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100: 2680-90.
30. Calara F, Dimayuga P, Niemann A, et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 18: 884-93.
31. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
32. Palinski W, Yla-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325-35.
33. Rosenfeld ME, Palinski W, Yla-Herttuala S, et al. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 10: 336-49.
34. Hammer A, Kager G, Dohr G, et al. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 704-13.
35. Hazen SL. Chisolm GM. Oxidized phosphatidylcholines: Pattern recognition ligands for multiple pathways of the innate immune response. Proc Natl Acad Sci USA 2002; 99: 12515-7.
36. Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis apoptotic clearance and protective immunity. J Clin Invest 2000; 105: 1731-40.
37. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: Molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-43.
38. Shaw PX, Goodyear CS, Chang MK, et al. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neoantigens and apoptotic cells. J Immunol 2003; 170: 6151-7.
39. Liuba P, Persson J, Luoma J, et al. Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol and are followed by thickening of carotid intima-media. Eur Heart J 2003; 24: 515-21.
40. Brown BG, Cheung MC, Lee AC, et al. Antioxidant vitamins and lipid therapy: End of a long romance? Arterioscler Thromb Vasc Biol 2002; 22: 1535-46.
41. Gershov D, Kim S, Brot N, et al. C-Reactive protein binds to apoptotic cells protects the cells from assembly of the terminal complement components and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med 2000; 192: 1353-64.
42. Hakala JK, Oksjoki R, Laine P, et al. Lysosomal Enzymes Are Released From Cultured Human Macrophages Hydrolyze LDL In Vitro and Are Present Extracellularly in Human Atherosclerotic Lesions. Arterioscler Thromb Vasc Biol 2003; 15: 15.
43. Han SR, Momeni A, Strach K, et al. Enzymatically Modified LDL Induces Cathepsin H in Human Monocytes: Potential Relevance in Early Atherogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 661-7.
44. Sakurada T, Orimo H, Okabe H, et al. Purification and properties of cholesterol ester hydrolase from human aortic intima and media. Biochim Biophys Acta 1976; 424: 204-12.
45. Bhakdi S, Torzewski M, Klouche M, et al. Complement and atherogenesis: Binding of CRP to degraded nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
46. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for CRP in atherogenesis: Complement activation by modified lipoproteins halts before the detrimental terminal sequence. Circulation 2004, in press.
47. Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99: 13943-8.
48. Taskinen S, Kovanen PT, Jarva H, et al. Binding of C-reactive protein to modified low-density lipoprotein particles: Identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 2002; 367: 403-12
49. Kruth HS, Zhang WY, Skarlatos SI, et al. Apolipoprotein B stimulates formation of monocyte-macrophage surface-connected compartments and mediates uptake of low density lipoprotein-derived liposomes into these compartments. J Biol Chem 1999; 274: 7495-500.
50. Langmann T, Schumacher C, Morham SG, et al. ZNF202 is inversely regulated with its target genes ABCA1 and apoE during macrophage differentiation and foam cell formation. J Lipid Res 2003; 44: 968-77.
51. Alving CR, Richards RL, Guirguis AA. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol 1977; 118: 342-7.
52. Chao FF, Blanchette-Mackie EJ, Tertov VV, et al. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J Biol Chem 1992; 267: 4992-8.
53. Hevonoja T, Pentikainen MO, Hyvonen MT, et al. Structure of low density lipoprotein LDL particles: Basis for understanding molecular changes in modified LDL. Biochim Biophys Acta 2000; 1488: 189-210.
54. Suriyaphol P, Fenske D, Zahringer U, et al. Enzymatically modified nonoxidized low-density lipoprotein induces interleukin-8 in human endothelial cells: Role of free fatty acids. Circulation 2002; 106: 2581-7.
55. Torzewski M, Klouche M, Hock J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369-78.
56. Seifert PS, Hugo F, Tranum-Jensen J, et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172: 547-57.
57. Steinbrecher UP, Longheed M. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscl Thromb 1992; 608-25.
58. Klouche M, Gottschling, Gerl V, et al. Atherogenic properties of enzymatically degraded LDL: Selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1376-85.
59. Schmiedt W, Kinscherf R, Deigner HP, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1790-5.
60. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor op and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8.
61. Patel S, Thelander EM, Hernandez M, et al. ApoE-/- mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 2001; 286: 164-70.
62. Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025-31.
63. Dansky HM, Charlton SA, Harper MM, et al. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997; 94: 4642-6.
64. Lehr HA, Sagban TA, Ihling C, et al. Immunopathogenesis of atherosclerosis: Endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104: 914-20.
65. Muhlestein JB. Chronic infection and coronary artery disease. Med Clin North Am 2000; 84: 123-48.
66. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347: 185-92.